Recalls and safety communications are not the same as a personal settlement, but they can support failure-to-warn claims. This page summarizes regulatory actions separate from infection symptom guides.
Duodenoscopes save lives by enabling ERCP and related interventions without open surgery, but they are also among the most technically complex reusable devices in a hospital. Over the last decade, public attention has focused on how hard-to-clean distal mechanisms, reprocessing workflows, and post-market reporting interact with patient outcomes. This article explains what duodenoscopes do, how Olympus duodenoscope recalls and safety corrections fit into a broader timeline, what changed in device features and hospital protocols, and why those facts matter to people researching an olympus duodenoscope lawsuit or duodenoscope infection lawsuit. It is informational only and not legal or medical advice.
Duodenoscopes and Their Role in ERCP
A duodenoscope is a specialized side-viewing endoscope used during endoscopic retrograde cholangiopancreatography (ERCP) to access the bile ducts and pancreatic duct for diagnosis and treatment (for example, stone removal, stent placement, and drainage). The procedure is common in gastroenterology because it can resolve obstructive problems quickly.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.
The clinical benefit comes with complexity at the tip: duodenoscopes typically include a steering “elevator” to help cannulate ducts and manipulate accessories. That mechanism is useful for precision and can also create tight spaces where bioburden is harder to remove than on a smooth exterior surface. That engineering reality is central to both infection-control policy and many civil claims.
The Olympus Duodenoscope Recall Story: A Timeline (Not One Single Headline)
When people search “Olympus duodenoscope recall,” they often expect a single date and a single fix. In practice, FDA databases and manufacturer communications show a series of actions—recalls, device modifications, field corrections, and urgent safety notices—spanning years. Understanding the timeline helps explain why safety work is iterative rather than “completed.”
According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.
A free evaluation can help you understand your options after a scope-related infection.
No obligation. Understand your legal options after a scope infection.
Request a free scope infection evaluationFDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
Rising national attention (2010s):: As infection clusters associated with reprocessed duodenoscopes drew scrutiny, FDA and professional societies intensified focus on reprocessing science, surveillance, and device design. That period set the stage for tighter expectations for manufacturers and hospitals.
FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
Design modifications and regulatory clearances:: FDA publicly described clearing Olympus duodenoscope design changes intended to reduce infection risk—commonly discussed in connection with the TJF-Q180V family—including engineering changes aimed at reducing fluid intrusion into areas that are difficult to reprocess. Public messaging at the time framed the goal as reducing the chance that soil could remain in hard-to-clean regions after reprocessing.
According to the American Society for Gastrointestinal Endoscopy, ERCP is performed in adults primarily for bile-duct stones and strictures—procedures that depend on duodenoscope design and reprocessing quality.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
Voluntary corrective actions and repairs:: Manufacturers have announced programs to repair or replace components so that facilities could implement updated designs. These actions are often categorized as recalls or corrections in FDA listings because they involve devices already in the field—even when the clinical purpose is risk reduction rather than a single “batch defect.”
Criminal enforcement related to reporting (2018):: The U.S. Department of Justice publicly resolved a matter involving Olympus entities and misdemeanor charges tied to failure to file required medical device reports concerning the TJF-Q180V duodenoscope in a defined historical window, alongside a substantial monetary component. That enforcement is about regulatory reporting obligations; it is frequently cited in public discussions alongside patient-safety concerns, but it is not the same as a court ruling on civil liability to any individual patient.
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
If you developed an infection after an Olympus scope procedure, you may have a claim.
Free, confidential case review for scope-related infections. Find out if you qualify.
Get a free scope infection case reviewAccording to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
Later recalls tied to device integrity:: FDA recall entries in subsequent years have included Olympus duodenoscope actions related to issues such as adhesive deterioration and seal concerns—problems that can be important because compromised seals may change how fluids move through internal channels during use and reprocessing.
According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
2025 field safety notices:: In 2025, Olympus issued urgent field safety notices discussed publicly in connection with multiple duodenoscope models (for example, lines such as TJF-Q190V, TJF-Q290V, and TJF-Q170V in regulatory summaries). Common themes in public descriptions include tightening expectations for how quickly manual cleaning must begin after a procedure, reducing pathways that allowed extended delay, and strengthening inspection expectations for distal tip components.
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
Patients who suffered infections after duodenoscope procedures may qualify for compensation.
No-cost evaluation for patients who suffered infections after an Olympus scope procedure.
Check your Olympus scope eligibilityIf you want primary sources, FDA maintains pages on infections associated with reprocessed duodenoscopes and posts recall entries as manufacturers report them—see the agency’s overview of reprocessed duodenoscope infections at FDA’s duodenoscope infection information. Our site summarizes litigation-facing developments on Olympus endoscope lawsuit news and updates.
Safety Protocols and Design Changes After Recalls: What Actually Changed?
Device-side changes (examples of themes, not a model-by-model manual)::
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
- Seals and fluid paths: Engineering changes have aimed to reduce ingress into regions that are harder to clean and verify.
- Instructions for use: Manufacturers revised reprocessing steps as post-market data accumulated—especially around timing from procedure end to manual cleaning start.
- Inspection: Some updates emphasized more rigorous distal-tip inspection practices than older “quick visual check” approaches.
Hospital-side protocol changes (common themes)::
FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
A free evaluation can help you understand your options after a scope-related infection.
No obligation. Understand your legal options after a scope infection.
Request a free scope infection evaluationAccording to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.
- Earlier precleaning and disciplined handoffs: Reducing the window between procedure completion and bedside precleaning.
- Supplemental measures in some centers: Ethylene oxide cycles where indicated, more conservative device rotation, and culture-and-hold strategies in selected facilities (program-dependent).
- Single-use components: Increased use of disposable distal end accessories where appropriate to reduce cross-patient risk at high-touch points.
Pre- vs post-recall safety features: a practical comparison
Before the modern wave of duodenoscope scrutiny:: Many programs relied heavily on high-level disinfection pathways and visual inspection, with less standardization around duodenoscope-specific time limits for cleaning start and less emphasis on disposable distal components.
FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
If you developed an infection after an Olympus scope procedure, you may have a claim.
Free, confidential case review for scope-related infections. Find out if you qualify.
Get a free scope infection case reviewAccording to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.
After repeated FDA communications and manufacturer field actions:: The system moved toward layered controls—better seals and labeling, tighter time windows for cleaning, stronger inspection expectations, and more hospital investment in reprocessing quality assurance.
FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
Effectiveness in the real world:: No protocol eliminates all infection risk; effectiveness depends on training, staffing, equipment maintenance, device wear, and adherence under pressure. That is why plaintiffs in a duodenoscope infection lawsuit often emphasize not only the device but also whether warnings and instructions matched what hospitals could reliably execute.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
How hospitals measure whether protocols “work” (high level):: Infection prevention teams often combine microbiological surveillance (when used), audits of reprocessing steps, leak testing, repair histories, and training compliance checks. A single missed step—delayed bedside precleaning, a damaged distal cap, or an inadequate brush pass—can undermine an otherwise strong program. That is one reason regulators treat duodenoscope safety as a system problem: device labeling, device condition, and human workflow must line up every time.
According to the American Society for Gastrointestinal Endoscopy, ERCP is performed in adults primarily for bile-duct stones and strictures—procedures that depend on duodenoscope design and reprocessing quality.
Patients who suffered infections after duodenoscope procedures may qualify for compensation.
No-cost evaluation for patients who suffered infections after an Olympus scope procedure.
Check your Olympus scope eligibilityFDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.
FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
For a patient-centered discussion of infection patterns, see infections and injuries from contaminated endoscopes.
Impact on Patients, Lawsuits, and Industry Standards
Patient risks:: When contamination occurs, patients may face severe infections, sepsis, prolonged hospitalization, and long-term complications. Immunocompromised patients can be disproportionately affected.
Legal landscape:: An olympus duodenoscope lawsuit may allege defective design, failure to warn, inadequate instructions, or negligence—depending on state law and records. Litigation can influence discovery into internal communications, training materials, and post-market surveillance—information that can matter both to individual cases and to public understanding.
A free evaluation can help you understand your options after a scope-related infection.
No obligation. Understand your legal options after a scope infection.
Request a free scope infection evaluationFDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
Industry feedback loop:: Lawsuits do not rewrite FDA regulations by themselves, but they can coincide with stronger surveillance expectations, clearer labeling, and more conservative hospital policies. The practical “standard of care” for reprocessing is partly written in IFUs and partly enforced through accreditation, infection prevention programs, and manufacturer corrections.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
FDA safety communications in 2015 and 2019 noted that certain Olympus TJF-Q180V duodenoscopes could harbor bacteria even after following manufacturer reprocessing instructions—a central theme in coordinated infection litigation.
Options for affected patients:: If you believe you were harmed, a confidential case review can help you understand whether your facts fit common screening criteria. Start at legal options for Olympus duodenoscope claims or contact us. Top Tier Legal, LLC is not a law firm; where appropriate, we may connect you with an independent law firm for evaluation.
Preventative Measures and Future Outlook
Ongoing protocols:: Expect duodenoscope safety to remain a moving target: IFU updates, recall corrections, and hospital retraining cycles are normal when devices are reusable and procedures are high volume.
According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
If you developed an infection after an Olympus scope procedure, you may have a claim.
Free, confidential case review for scope-related infections. Find out if you qualify.
Get a free scope infection case reviewAccording to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.
Technology direction:: More disposable components, improved sealing, automation aids in reprocessing, and better traceability (device history, repair logs) are common themes in manufacturer roadmaps and hospital purchasing discussions.
FDA recall data show that Class I device recalls—the most serious category—represent a small fraction of annual actions but capture products where use may cause serious injury or death.
Purchasing and accountability:: Some facilities have tightened replacement cycles for older duodenoscopes, prioritized service contracts that include rapid repair of elevator-related wear, and standardized documentation when a scope is pulled from service after difficult cases. Those operational choices matter because they reduce the chance that a marginal device remains in circulation.
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
Regulatory posture:: Timely medical device reporting and transparent post-market surveillance remain central—especially after public enforcement cases tied to reporting obligations.
Legal implications:: As long as serious infections remain plausible under real-world conditions, duodenoscope infection lawsuit filings may continue—particularly where plaintiffs can tie timelines, cultures, and device identifiers together. Courts decide individual cases; trends in labeling and hospital practice still matter to prevention.
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
For broader medical-device context beyond duodenoscopes, read medical device lawsuits and medical device recalls and patient rights.
Patients who suffered infections after duodenoscope procedures may qualify for compensation.
No-cost evaluation for patients who suffered infections after an Olympus scope procedure.
Check your Olympus scope eligibilityFAQs: Recalls, Infections, and Legal Recourse
- Q: Does a recall automatically mean I have a lawsuit?
- No. A recall or field correction is one piece of context. Claims depend on individual facts, records, and deadlines.
According to peer-reviewed endoscopy literature, duodenoscope-associated outbreaks declined after institutions adopted culture-and-quarantine surveillance, but litigation focuses on earlier periods when protocols varied.
The FDA estimated in 2015 that more than 500,000 ERCP procedures are performed in the United States each year—procedures that rely on duodenoscopes with complex elevator-channel designs that are difficult to reprocess.
- Q: Is every post-ERCP infection caused by a duodenoscope?
- No. Infections can come from many clinical sources. Legal screening focuses on timing, microbiology, investigations, and device documentation.
- Q: What should I do if I received a hospital letter about scope cleaning?
- Preserve the letter and your procedure records and ask your clinicians any urgent medical questions first. For legal timing questions, speak with a licensed attorney—do not wait simply because you are unsure about the device brand.
According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.
- Q: How do I learn terminology before speaking with counsel?
- See our endoscope lawsuit guide and what the Olympus endoscope lawsuit refers to.
According to CDC outbreak investigations, carbapenem-resistant *Enterobacteriaceae* (CRE) linked to contaminated duodenoscopes caused hospital outbreaks at multiple U.S. centers between 2012 and 2015, prompting FDA safety communications.
A free evaluation can help you understand your options after a scope-related infection.
No obligation. Understand your legal options after a scope infection.
Request a free scope infection evaluationTop Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney–client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
